tiprankstipranks
Artrya Limited (AU:AYA)
ASX:AYA
Australian Market

Artrya Limited (AYA) Share Price & Analysis

1 Followers

AYA Stock Chart & Stats

Day’s RangeAU$0 - AU$0
52-Week RangeAU$0.16 - AU$0.42
Previous CloseAU$0.31
Volume4.85K
Average Volume (3M)51.94K
Market Cap
N/A
Enterprise ValueN/A
Total Cash (Recent Filing)AU$35.56M
Total Debt (Recent Filing)AU$1.37M
Price to Earnings (P/E)-2.1
Beta2.07
Aug 29, 2024
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.15
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. Volume51,940
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0

Financials

Annual

Options Prices

Currently, No data available
---

Ownership Overview

14.60%0.00%0.00%85.40%
14.60% Insiders
0.00% Other Institutional Investors
85.40% Public Companies and
Individual Investors

AYA FAQ

What was Artrya Limited’s price range in the past 12 months?
Artrya Limited lowest share price was AU$0.16 and its highest was AU$0.42 in the past 12 months.
    What is Artrya Limited’s market cap?
    Currently, no data Available
    When is Artrya Limited’s upcoming earnings report date?
    Artrya Limited’s upcoming earnings report date is Aug 29, 2024 which is in 123 days.
      How were Artrya Limited’s earnings last quarter?
      Artrya Limited released its earnings results on Feb 28, 2024. The company reported -AU$0.088 earnings per share for the quarter, beating the consensus estimate of -AU$0.095 by AU$0.007.
        Is Artrya Limited overvalued?
        According to Wall Street analysts Artrya Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Artrya Limited pay dividends?
          Artrya Limited does not currently pay dividends.
          What is Artrya Limited’s EPS estimate?
          Artrya Limited’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does Artrya Limited have?
          Artrya Limited has 78,703,995 shares outstanding.
            What happened to Artrya Limited’s price movement after its last earnings report?
            Artrya Limited reported an EPS of -AU$0.088 in its last earnings report, beating expectations of -AU$0.095. Following the earnings report the stock price went same 0%.
              Which hedge fund is a major shareholder of Artrya Limited?
              Currently, no hedge funds are holding shares in AU:AYA
              ---

              Artrya Limited Stock Smart Score

              6
              Neutral
              1
              2
              3
              4
              5
              6
              7
              8
              9
              10

              Fundamentals

              Return on Equity
              -39.26%
              Trailing 12-Months
              Asset Growth
              -31.04%
              Trailing 12-Months

              Company Description

              Artrya Limited

              Artrya Ltd is a medical technology company engaged in developing software that automates the analysis of heart computed tomography (CT) scans to assist in the diagnosis of Coronary Artery Disease.
              ---
              Similar Stocks
              Company
              Price & Change
              Follow
              Sonic Healthcare Limited
              PainChek Ltd
              Beamtree Holdings Ltd
              Popular Stocks
              ---
              What's Included in PREMIUM?
              Make informed decisions based on Top Analysts' activity
              Know what industry insiders are buying
              Get actionable alerts from top Wall Street Analysts
              Find out before anyone else which stock is going to shoot up
              Get powerful stock screeners & detailed portfolio analysis